2016
DOI: 10.17795/ijcp-4993
|View full text |Cite
|
Sign up to set email alerts
|

Cancer-Testis Antigens: A Novel Group of Tumor Biomarkers in Ovarian Cancers

Abstract: Context: Ovarian cancer is the most fatal gynecological malignancy with no effective screening strategy for early detection. As most cases are being detected in advance stages, conventional therapies are not beneficial for the majority of patients. Cancer-testis antigens (CTAs) are a group of tumor associated antigens with specific expression pattern in cancers which potentiate them for application as cancer biomarkers and targets for immunotherapy. Evidence Acquisition: We performed a computerized search of t… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
5
0

Year Published

2017
2017
2024
2024

Publication Types

Select...
4
1

Relationship

1
4

Authors

Journals

citations
Cited by 7 publications
(5 citation statements)
references
References 77 publications
0
5
0
Order By: Relevance
“…Therefore, a peptide vaccine consists of their immunodominant epitopes can exhibit high coverage for a vast variety of cancers. In cancer patients, activation of both cellular and humoral immune response against SYCP1 and ACRBP have been reported which demonstrate immunogenicity of these antigens in the autologous host (Taherian-Esfahani 2016). Cancer vaccines should be assessed by animal experiments before interring clinical trials.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…Therefore, a peptide vaccine consists of their immunodominant epitopes can exhibit high coverage for a vast variety of cancers. In cancer patients, activation of both cellular and humoral immune response against SYCP1 and ACRBP have been reported which demonstrate immunogenicity of these antigens in the autologous host (Taherian-Esfahani 2016). Cancer vaccines should be assessed by animal experiments before interring clinical trials.…”
Section: Discussionmentioning
confidence: 99%
“…SYCP1 and ACRBP are members of CTAs families in which the spontaneous immune responses against both of them have been detected in cancer patients (Taherian-Esfahani 2016). SYCP1 interacts with different proteins as a part of the synaptonemal complexes during meiosis and ACRBP participates in spermatogenesis and sperm capacitation (Whitehurst et al 2010;Costa et al 2005;Nielsen and Gjerstorff 2016).…”
Section: Introductionmentioning
confidence: 99%
“…For instance, estrogens participate in tumor progression by increasing cell proliferation in addition to enhancing invasion or cell mobility [2] . Based on histopathology, immunohistochemistry, and molecular genetic studies, malignant epithelial tumors of ovary are classified into serous carcinoma, endometrioid carcinoma, clear-cell carcinoma, and mucinous carcinoma [3] . Dysgerminoma and teratoma are also two types of germ cell tumors of ovary [4] .…”
Section: Introductionmentioning
confidence: 99%
“…The detection of the limited expression patterns of CTAs, the specific humoral and cellular responses along with the inducible immune responses against certain CTAs have provided the evidence for the suitability of CTAs as ideal therapeutic targets for immunotherapy [100,101]. Subsequently, some CTAs that have tumor-restricted expression and induce immune system responses could enter clinical trials studies for improving the survival of patients [102,103].…”
Section: Ctas In Cancer Immunotherapymentioning
confidence: 99%